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Theneedforassessingnoncancerrisksforagentstowhichhumansareroutinely exposedindoorsarisesfromthelarge
amountoftimespent indoors (i.e., employed persons spend about60% oftheirtimeat homeindoors, 30% at workin-
doors,and5%intransit). Sourcesofairpoilutantsincludeheatingandcooligsystems,combustionappliances, personal
useproducts, furnishings,tobaccoproducts, pesticides, biodefluentsfromhumansandanimals,andothermicrobialcon-
taminationsuchastoxinsfromnmolds. Thepurposeofthispaperistodescribecurrentdose-responsea entmhods
appliabletoas riskfollwingexposuretoindoorair uant Theroleofstuture-activityriationships inhazard
identification isalsodescribed.
Risk mentsfromexposuretoindoorairpollutantsrequireexposure ssementsanddose-responseassessments.
Dose-responseassessment methodologies includethe inhalation referenceconcentration (RfC),structure-activity rela-
tionships,dose-rponse models, andthedecisionanalyticapproach. TheRfCisanestimate(withuncertaintyspanning
perhapsanorderofmagnitude)ofadailyexposuretothehumanpopulation(includingsensitvesubgroups)thatislike-
lytobewithoutanappreciableriskofdeleteriouseffectsduringalifetime. ThecurrentRfCmethodprovidesguidelines
for mkingthenecessarydometricadjustmentsforgasesandaerosols. Humanequivalentcocentus forno-observed-
adverse-effectlevelsinanimalsaredeterminedbyusingmathematicalrelationshipsthatadjustforregionaldeposition,
solubility,ventilation rate,andblood:airpartitioncoefficients. TheRfCmethodologyexistsasaninterimmethodology.
Futurescientific advancements areexpected tofurther refinetheapproach.
Introduction
The need for assessing noncancer risks for agents to which
humans are routinely exposed indoors arises from the large
amountoftime spentindoors. Ott(I)hasreportedthatemployed
personsspendabout60% oftheirtimeathomeindoors, 30% at
workindoors, and5% intransit. Sourcesofairpollutants include
heating andcooling systems, combustion appliances, personal
useproducts, furnishings, tobaccoproducts, outsidepollutants
and soil gases, cleaning and maintenance products, pesticides,
bioeffluentsfromhumansandanimals, andothermicrobial con-
tamination such as toxins from molds (2). Concentrations of
somecompounds (e.g., volatileorganics) mayreachconcentra-
tions 100-foldhigherindoorsthanoutdoors. The purposeofthis
paperis todescribe currentdose-response assessmentmethods
applicable to assessing risk following exposure to indoor air
pollutants. The roleofstructure-activity relationships inhazard
identification is also described.
The National Research Council (3) has summarized risk
assessment and its application to indoor and outdoor air pol-
lutants and air pollution-associated health effects. Four basic
steps ofrisk assessment wereoutlined as follows: hazard iden-
tification, exposure assessment, dose-response assessment, and
riskcharacterization. Hazard identification isthedetermination
ofwhether aparticular chemical is or is notcausally linked to
particular health effects. Dose-response assessment is the
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quantitative relationshipbetweenthemagnitudeofexposureand
theoccurrenceofhumanhealtheffects. Exposureassessmentis
the determination of the extent of human exposure including
evaluation ofthe exposure and the number ofpeopleexposed.
Riskcharacterization isthedescriptionofthenature, andoften
themagnitude, ofhumanrisk, including attendantuncertainty.
Essentially, riskassessment is an integrationofdose-response
assessment and exposure assessment. While the National
Academy ofSciencehasdescribed thefourcomponentsofrisk
assessment as separate entities, hazard identification and dose
responsemaybeconductedconcurrently whendealingwithnon-
cancerendpoints. Developmental, reproductive, andneurotox-
icity riskassessmentguidelinescombinethesetwocomponents.
Current dose-response assessment methods are described
here. Theinteriminhalationreferenceconcentration method is
expanded in greatest detail (4). Also described are meth-
odologies forperformingdose-responseassessmentsbymodel-
ingdose-response relationships andusingthedecisionanalytic
approach (5).
Inhalation Reference Concentration
The U.S. EPA has chosen the reference concentration (RfC)
methodology to clarify aspects of risk assessment formerly
coveredbytheacceptabledaily intake(ADI). TheRfCisdefined
as an estimate (with uncertainty spanning perhaps an orderof
magnitude) of a daily exposure to the human population (in-
cluding sensitive subgroups) that is likely to be without an ap-
preciable risk of deleterious effects during a lifetime. TheC. R. SHOAF
requirements forestimating an inhalation RfC aretoxicitydata,
uncertainty factors, andpossibly amodifying factor. TheRfC is
determined as
RfC = NOAEL/(UF x MF)
where NOAEL = no-observed-adverse-effect level; UF =
uncertainty factor; and MF = modifying factor.
Theoperatingassumption in RfCdevelopmentisthatadose
threshold exists at or above which an adverse effect will be
evoked in anorganism ifexposure occursthroughoutalifetime.
Thisassumption iswell-founded formanycompoundsthathave
definedtoxicity mechanisms(6), thoughinconsistencies in sub-
population thresholds may make the assumption invalid when
considering differentpopulations (7). The NOAEL is the first
basis forevaluating the RfC. It is derived from toxicity data in
which a critical effect having a dose-response relationship is
identified. The NOAEL is an exposure level for which no
statistically orbiologicallysignificantincreasesinfrequencyor
severityofadverseeffectsoccurinanexposedpopulation com-
pared to a control population. All effects that occur are not
necessarily adverse. Adverseeffects are functionalimpairments
or pathological lesions that may be manifested in the perfor-
mance ofanorganism ortheorganism'sresponsetoachallenge.
The NOAEL, rather than the occupational exposure limit
(OEL), the frank effect level (FEL), or the NOEL, is used to
determinetheRfC. OELsare notusedforthederivationofRfCs
for several reasons: a) OELs are not necessarily based on
chroniceffectsofsimilarseverity totheRfC;b)OELsarebased
on intermittentexposure;c) someOELsarebasedonstudiesthat
have not been reviewed orpublishedintheopenliterature, i.e.,
some corporatestudies;d)theOELtoxicitydatamaydifferfrom
thedata usedbytheU.S. EPA inweightofevidence;ande)OELs
aredesignedtoprotectthehealthyworker, notthe mostsensitive
subgroup (e.g., children). FELs are unsuitable fordetermining
RfCs because mortality and frankly apparent and irreversible
functional impairment are far removed quantitatively from
chronicNOAELs and LOAELs. Thus, ifafrankeffectisallthat
is detected, thedatabase has failed to establish a level at which
no adverseeffects occurbased uponthemostsensitiveendpoint.
A single NOEL with no other dose-response data is also un-
suitable forthederivationofanRfCbecauseitdoes notidentify
a level at which no adverse effects occur.
The database used in selecting the critical study fromwhich
the NOAEL is determinedcontributes to the confidence in the
resulting RfC. Human data from epidemiological or clinical
studies thatdescribe the exposure levels arepreferredandgive
a high confidence in the database because extrapolation from
animal studies is notrequiredwith itsattendantuncertainties. If
human studies are notavailable, high confidence in an animal
databaserequires twomanmmaliansubchronicorchronictoxicity
studies in different species, one mammalian two-generation
reproductivetoxicity study anddevelopmentaltoxicitystudiesin
different species. A minimum database is a single, well-
conducted, subchronic mammalianbioassay.
Wheneverpossible, theRfC shouldbebased ondatafromin-
halation exposures. However, inhalation data are not always
available. Ifdata fromother exposure routes areused, then ad-
ditional uncertainties occur. Portal-of-entry effects in the lung
mustbe ruled outbeforeextrapolating from exposureby other
routes. Ifportal-of-entryandfirst-passeffects canberuledout,
estimates ofequivalent doses can be based on available phar-
macokineticdataforbothroutes, absorptionefficiencybyeach
route, comparative excretion when metabolism is equivalent
from both routes, and comparative toxicity when effects are
equivalentbybothroutes. However, thisinformationisavailable
for relatively few chemicals. Metals, irritants, and sensitizers
should be cautiously used for route-to-route extrapolation.
Metalsthatcanprovoke immuneorhypersensitivity reactions,
including asthma, are mercury, gold, platinum, beryllium,
chromium, andnickel (8). Thebiologically basedmodelsused
inroute-to-routeextrapolationsdonotaccountforirritationand
sensitizationchangesthatmightoccurby eitheroral or inhala-
tion routes.
TheUFsaregenerallyorder-of-magnitudevaluesbasedonthe
chosencriticaleffectandrepresentthesecondbasisforthescien-
tificevaluationoftheRfC. A 10-folduncertainty factorisinvoked
to account for the variation in sensitivity among human sub-
populations. Extrapolation ofanimal data to average, healthy
humansalsoinvokesa 10-folduncertaintyfactor. Whenlessthan
chronicNOAELsareusedasabasisfortheRfC, a 10-folduncer-
tainty factor is used (unless the critical effect is developmental
orreproductivebecausea singleexposure may be sufficientto
produce an adverse effect). When the RfC basis is a lowest-
observed-adverse-effectlevel (LOAEL)ratherthanaNOAEL,
a 10-folduncertaintyfactorisused. Ifthedatabaseisincomplete
(e.g., onlyasingleanimalstudyisavailable), a 10-folduncertain-
tyfactorisused. TheRfCmaybealteredwithamodifyingfac-
tor (MF) from 1 to 10 ifthe critical study has scientific weak-
nessesoruncertaintiesor0to 1 ifthecriticalstudyhasattendant
strengths.
TheRfCconsiderstherelationshipbetweenexposureconcen-
trationanddosedeliveredtothe targetsite. The respiratory tract
dosimetry ofgases andparticlesdiffers across species, though
similar respiratory tract regions are considered (9,10). The
respiratory tractanatomy, physiology, xenobiotic metabolism,
andbiochemistry (mucousinteraction)andthephysicochemical
properties of the inhaled toxicant account for differences in
deposition across the species. Evaluation of dose-response
curves acrossspeciesrequiresknowingthedosedeliveredtothe
targettissue, andthetargettissuedoseisdeterminedbyabsorp-
tion, distribution, metabolism, andexcretion. TheRfCprocess
assumesthateitherabsorptionisequivalentacrossspeciesorthat
thedifferencesinabsorptionaresominimalthattheinterspecies
uncertainty factor accounts for them along with other phar-
macokinetic and pharmacodynamic differences. Use ofphys-
icochemical, physiological, anatomical, and biochemical ad-
justments will minimize theuncertainty ofRfC development.
Becauseofdosimetricdifferencesbetweentheexperimental
species andhumans, NOAELs determined fromexperimental
exposure levels in animals need to be adjusted to human
equivalentconcentrations(HEC). ThecalculationofHECsfor
theNOAELrequires several steps. Figure 1 shows aschematic
ofthe steps foradjustingaNOAEL toaNOAEL(HEC). First, the
exposureconcentrationsinpartspermillionmustbeconverted
tomilligramspercubicmeter. Next, theexposureregimenmust
beconvertedtoacontinuous(24-hr) lifetime(70-year)exposure
(except fordevelopmentaland reproductivetoxicity endpoints
because a single exposure may be sufficient to produce an
adverse effect). Ifthe exposure is to a particle, then physical
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FIGURE 1. Flowchart forcalculating humanequivalentconcentrations. Deci-
sion processes for aerosols and gases are shown for respiratory and ex-
trarespiratory target effects.
descriptions of the particles must be obtained to describe the
exposure andpredict whethera respiratory orextrarespiratory
effect is likely to occur. Ifexposure is to agas, thetemperature
and pressure conditions must be determined. Gases may also
haverespiratory orextrarespiratory effects. Respiratory effects
may resultfrom reactiveorsolubleagents. Extrarespiratory ef-
fects ofgases depend upon periodicity ofthe exposure.
Concentration Conversion
Ifexposure levels are expressed in units ofpartsper million,
then the ideal gas law can be used to convert from parts per
million to milligrams percubic meterusing Eq. (1):
mg/m' = ppm x g-mole/22.4 L x MW/g-mole x2731T x Pi76O mm Hg x 103
L/m' x 103 mg/g (1)
where ppm = concentration expressed on a volumetric basis
(L/106L), MW = molecular weight in grams, 22.4 L = the
volume occupied by 1 g-mole ofa gas at0'C and, 760 mm Hg,
T = actual temperature in degrees Kelvin, and P = actual
pressure in mm Hg. Exposures may typically occur at 25°C
rather than 0°C. The volume of 1 g-mole ofperfect gas at 25°C
is24.45 L, andtheconversion is simplified tomg/m3 = ppm x
MW/24.45.
Dose Duration Adjustment
A dose duration adjustment is necessary when developing
RfCs becausethey are based oncontinuous exposure, and sup-
portingexperimental exposureregimens arelikelytobediscon-
tinuous. Normalization of discontinuous exposure to lifetime
continuous exposureisachievedbythefollowingequation forthe
adjusted NOAEL (NOAELIADJl).
NOAELID(mg/m'
= E(mg/m3) x D(hours/day/24 hours)
x W(daysn7 days) (2)
where E = experimental exposure level, D = numberof(hr ex-
posed/day)/24hr, andW = numberof(daysofexposure/week)/7
days.
Duration and solubilityeffects mayaffecttheaccuracy ofthe
simpledirect relationshipexpressed in Eq. (2). Ideally, theex-
posure duration should includetheperiod oftimeduring which
toxiceffects sharplychange (11). Tissueconcentrations ofagas
alsovarywith lipidsolubility. Gaseswithhighblood-to-airpar-
titioncoefficientsarelipidsoluble. First-orderkineticsofuptake
and elimination are also assumed by Eq. (2).
Human Equivalent Concentrations
AftertheNOAEL isadjustedfordurationofexposure, HECs
foreitherparticlesorgases mustbecalculated. The respiratory
anatomy, ventilation characteristics, and biochemical and
metabolic reactions of the exposed species significantly in-
fluences the HEC ofan inhaled particle or gas.
Anatomical and physiological differences in humans and
animals affect air flow in the respiratory system. The three
regions of the respiratory system, nasopharyngeal, tracheo-
bronchial, and pulmonary, arecharacterized bydifferent struc-
ture, size, and function, and the anatomy, physiology, and
clearance mechanisms ofthese regions determine the retained
doseofparticles intherespective regions. Thenasopharyngeal
region, alsoreferredtoastheextrathoracic region, consistsofthe
anterior nares and extends back and down to the level of the
larynx. This region is characterized by a lining of vascular
mucous epithelium. Filtration, humidity and temperature
changes, and absorption of inhaled gases also occur in the
nasopharyngeal region. Thetrachea, bronchi, andbronchioles
are the conducting airways that compose the tracheobronchial
region. The upperairways (trachea and bronchi) ofthis region
are lined with a ciliated epithelium coated with a thin layer of
mucus. The mucociliary escalator of the conducting airways
clears particles from the deep lung to the oral cavity, and the
mucuscanreactwithorabsorbgases, therebychanging thedose
totheepithelium. Theairwaybranchingpatternsanddimensions
arecriticalindeterminingparticledepositionandgasabsorption.
Thepulmonary regionconsists offirst-order respiratory bron-
chioles, alveolar duets, and alveolar sacs. This region is the
primary siteofgas exchange between the environment and the
blood.
Particle Effects
The deposition ofinsoluble particles in various parts ofthe
respiratory system are shown in Figure 2A for nasal inhalation
and in Figure2Bfororal inhalation (12). Particlesgreaterthan
2.5 Zm mass median aerodynamic diameter are deposited
preferentially in the nasopharyngeal (extrathoracic) region.
Comparedtonasal inhalation, oralinhalation shiftsthedeposi-
tionofparticles tohigherfractions forboththetracheobronchial
andpulmonary regions.
The HEC calculations forparticlesalso rely onthephysico-
chemical characteristics ofparticles andtemperature andpres-
sureconditions forgases. Physicochemical characteristicsaffect
particle deposition and retention within the respiratory tract,
translocation withintherespiratory system, distribution toother
tissues, andtoxiceffects. Thesizesofmostparticlesapproximate
alog-normaldistribution. Assuming alog-normalfunction, the
size ofparticles may be described by the mass median aero-
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thelate 1970scouldnotproduceaerosolsconsistently lessthan
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3 .tmandthedistributioncharacteristic forthegivengeneration
system thatyields the mostconservative HEC, theNOAEL(HEC)
can be derived. Ifcount median diameter is given rather than
MMAD, theHatch-Choateequationscanbeusedforconversion
(14). Adjusting deposition efficiency for nonhygroscopic par-
ticles isrecommendedbecausemodels indicatesuchanadjust-
ment would overestimate deposited dose for the smaller dif-
fusion-dependent hygroscopic particles.
100.00
HEC forRespiratory Effectsfrom Particles
Depositionefficiencyandparticledistributioninformationcan
be used to calculate the deposited dose of exposure particles
whentheseparticlesexistasaninsolubleaerosol. Thedeposited
fractionforanyregionoftherespiratory systemisafunctionof
deposition efficiency and particle mass fraction. Integration
across all particle sizes will give the mass deposition in a par-
ticular region. Deposition in a particular region for a given
species isobtainedfromtheproductofthefractional deposition,
v ventilation rate, andexposureleveldividedbytheregional sur-
facearea. Thus, assumingtheequivalentdoseacross species is
theaerosolmassdepositedperregionalsurfacearea,theregional
depositeddose(RDD)fortheextrathoracic regionisdetermined 100.00 as in Eq. (3).
B
FIGURE 2. (A) Diameter ofspherical particle with density of 1 g/cm3 (sm).
Total and regional deposition fractions for aerosols entering the nose for
various sizes ofinhaled, airborne spherical particles with physical density
of I g/cm3 in the human respiratory tract ascalculated by the International
Commission on Radiological Protection (ICRP) Task Group on Lung Dy-
namics (23) for nasal breathing at a rate of 15 breaths per min (BPM) and
tidal volume(TV) of750mL. (B)Total andregional deposition fractions for
aerosols entering the mouth for various sizes ofinhaled, airborne spherical
particles with physical density of I g/cm3 in the human respiratory tract as
calculated by the International Commission of Radiological Protection
(ICRP) Task Group on Lung Dynamics (23) with the head airway deposi-
tion functiongiven by Raabe (24) fororal breathing at a rateof 15 BPMand
TV of750 mL.
dynamic diameter (MMAD). Ifparticles are nonspherical in
shape, then they should be treated as equivalent spheres, and
their aerodynamic diameter taken into account. The
aerodynamic diameter is the diameter of a unit density sphere
having the same terminal settling velocity as the particle
whatever its size, shape, and density. Aerodynamic diameter
shouldbeconsideredfortheparticlesdepositedbyimpactionand
sedimentation. Sincethetoxiceffecttothelowerrespiratory tract
willincrease asthe massoftheparticlespenetrating tothedeep
lung oralveolar regionincreases, theMMADbecomes impor-
tant. Sincetheparticlepopulation isknown tohave alog-normal
distribution, it canalsobecharacterizedbythegeometric stan-
dard deviation (ag). Monodisperse aerosols have agvalues less
than 1.2. Theabilityofparticles totakeonwater(hygroscopicity)
may also affect their sizeand, therefore, their deposition.
Someadjustmentsandassumptions may berequiredwhen us-
ingavailabledatatocalculate an RfC. Older studiesthatdo not
provide MADD and ag values should be suspect for use in
calculating RfCs. Aerosol-generating equipment in use before
10-6yv n
RDDET J P,El
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(3)
where Pi = the particulate mass fraction in the exposure size
distribution (MMAD, org), E, = thedeposition efficiency ofthat
sizedistribution (MMAD, ag) intheextrathoracic region forthe
speciesofinterest, i = size range, n = numberofsize ranges, Y
= exposure level (mg/m3), VT = tidalvolume (mL), f = breath-
ing frequency (breaths/min), and SET = surface areaofthe ex-
trathoracic region (cm2).
Depositionofonly onesize range(i)ofparticles for one region
(extrathoracic) isshown inEq. (3). Toxiceffectsinotherregions
necessitate useofparametersdefiningtheaffectedregion. Sum-
mation overmultiple(n)particle rangesandmultipleregions(ex-
trathoracic, tracheobronchial, pulmonary, thoracic, ortotal) is
possibleusingthe sameexpressionandknowledgeofthe respec-
tivesurface areas(S), particulate massfractions(P), anddeposi-
tion efficiency (E).
TheRDD canbecalculated foreachspeciesofinterestusing
the same MMAD and a.. The regional deposited dose ratio
(RDDR) is used to convert the adjusted NOAEL to the human
equivalent concentration as follows:
NOAEL mEcl(mg/m3) = NOAELjADj(mg/m3) x RDDR (4)
where NOAELIHECJ = the NOAEL human equivalent concen-
tration, NOAELIADJJ = theNOAELadjustedforduration accor-
ding to Eq. (2), and RDDR = (RDDANIMAL)/(RDDHUMAN), the
ratio of regional deposited dose in animal species to that of
humans for the region andtoxic effectofinterest.
Becausedosimetricdatafromrats areavailable, theRDDRof
insolubleparticles for rats tohumans has beencalculated for ag
of1.2, 1.4, 1.8,2.0,2.2, and2.4 at MMAD of0.lOOto 10.000 tm
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for an extrathoracic, tracheobronchial, pulmonary, thoracic,
(tracheobronchial plus pulmonary), or total respiratory (ex-
trathoracic plus thoracic) effect (4,15).
HEC for Extrarespiratory Effects ofParticles
If the toxic effect of an inhaled particle is outside the res-
piratory tract, then the effect is extrarespiratory, and the
equivalent dose across species is based on the particle mass
deposition per body weight. In the absence ofdata indicating
otherwise, 100% ofthedeposited dose isassumedavailable for
systemic absorption and circulation. However, clearance and
distribution datacouldalterthisassumption. Eq. (5) showsthe
expression for calculating the extrarespiratory (ER) RDD.
RDD LO 6YV; PTE (5)
BW iBW
whereEi = the distribution efficiency ofthat size distribution
(MMAD,a.) intheentirerespiratory tract forthespeciesofin-
terest, BW = bodyweight(kg), andothervariablesareasforEq.
(3).
Theratiooftheanimal RDDtothehumanRDDisusedtocon-
vert the adjusted animal NOAEL to a NOAEL as a human
equivalent concentration as in Eq. (6).
NOAELIHM(mg/m3) = NOAELlA (mg/m3) x RDDRER (6)
where NOAELIHECI = the NOAEL human equivalent concen-
tration, NOAELIADJI = theNOAELadjustedforduration accor-
ding to Eq. (2), and RDDER = (RDDER)A/(RDDER)H, the ratio
ofthedoseavailableforuptake fromtheentirerespiratory system
ofthe experimental animal species tothat ofhumans.
The RDDRforratstohumansforinsolubleparticles inarange
of 1.2 to 2.0 agand an MMAD of0.100 to 10.000 ,um have been
calculated for the extrarespiratory region (4,15).
Gas Effects
Interspecies dosimetry ofgases and vapors should be deter-
minedtoextrapolatetoxicological effectsfrom animal studies to
humans. Physiological modeling maybeused topredicteffects
fromreactivegasesormetabolically activatedgases. Uptakeand
distribution ofmetabolically activated gasesdependontheblood
andtissue solubility andphysiological parameters such as ven-
tilation and tissue mass and perfusion. Kinetic parameters of
metabolismareimportanttoobecausetoxicity mayberelatedto
stable orreactive metabolites oftheparentcompound. Model-
ingtoxicitybasedonmechanismofactionincomparativespecies
requires much data, which are seldom available. Interspecies
doseadjustments will become moreprecise as soonasanatomic
andphysiologicparametersofthespeciesandphysicochemical
determinants ofthe gases are known. Better definition of ex-
posure concentration and duration conditions will also be re-
quired for accurate modeling.
HEC for Respiratory EffectsofGases
Reactivegasesmayhavetheirtoxiceffectinthelung. Likethe
approach forinsolubleparticles, thetoxiceffectis relatedtothe
massoftoxicagentabsorbedbythesurfaceareaoftheregionof
interest. Theventilatory rateaffectsthedose, thoughnotdirectly.
Thegeneraltermfortheregionalgasdose(RGD)isshowninEq.
(7).
RGD=-104W/
S (7)
whereS = regional surfacearea(cm2)oftoxiceffectobserved,
andothervariables areaspreviouslydefined. TheRGDmaybe
simplified from unit ofmilligrams per minute per square cen-
timeter to milligrams per square centimeter by substituting
minute volumeratherthantidal volume (VT) andbreathing fre-
quency (f). Theventilation rateoftheregionofconcern (e.g., ex-
trathoracic, tracheobronchial, pulmonary, thoracic, or total)
should beusedtoobtaintheeffectivedosimetry. The RGDs for
theappropriate species andhumans canbecompared toderive
the regional gas dose ratio (RGDR), which is used to dosi-
metrically adjust the experimental NOAEL to a human
equivalentconcentration, as in Eq. (8).
NOAEL[HECI (mg/m3) = NOAELI,D,] (mg/m3) x RGDR (8)
where RGDR = (RGD)ANIMAL/(RGD)HUMAN, the ratio of
regional gas dose in animal species to that ofhumans for the
region and toxic effect of interest, and other variables are as
defined in Eq. (6).
Somegasesmaybehighly solubleinthebloodandyethaveef-
fectsonlungtissue. Thelungeffectofthesegasesisindirect, and
thedosimetry shouldbetreatedliketheextrarespiratory effects
for gases as described below.
HEC forExtrarespiratory Effects ofGases
Theapproach todetermineHECsforextrarespiratory effects
of gas exposures should estimate NOAELIHECJ values as a
function of the average animal exposure concentration, i.e.,
NOAELIADJI. Four methods for achieving these estimations
havebeen studied (16). Themethods arereferredtoas propos-
ed, established, similar, andoptimal. Theproposed method is
a simple methodology for extrapolating dosimetry from rat
studies tohuman. Thismethodassumestheeffectivedoseisthe
arterial blood concentration or its concentration multiplied by
time and that theblood:airpartition coefficient forthe animal
(XA) islessthanorequal totheblood:airpartitioncoefficient for
the human (XH). The proposed method is more conservative,
i.e., gives lower HECs, than other methods, including: a) the
establishedmethod, whichadjustsdosimetry simply onthebasis
ofventilation ratedividedbybodyweight; b) amethod similar
totheoptimal model method, whichuseshumanphysiological
parametersandanimalparameters scaled fromthese; andc)the
optimal method which uses physiologically based pharma-
cokinetic (PB-PK) model requiring a complete set ofphysio-
logical parameters for animals and humans.
Physiologically basedpharmacokinetic models may usefive
compartments, including gas exchange, fat, poorly perfused,
richlyperfused, andliver/metabolizing tissuegroups todescribe
the body (17). The relevant physiological and biochemical
parametersandtheagent'smechanismofactionareneededtouse
the PB-PK model approach. However, these data are not
available for most gases. The relationship ofthese methods is
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shown in Figure 3 (16), which shows thattheproposedmethod
produces the most conservative NOAEL!HECI from the animal
NOAEL. Because theblood:airpartition coefficients are more
readily available than arecompletephysiological parameterdata,
a ratio ofanimal to human blood:air partition coefficients is a
simple, conservative default thatclosely approaches theoptimal
method.
Ifthe concentration ofgas in the arteries leaving the lung is
periodic, thentheblood:airpartitioncoefficient willcontrolthe
arterial concentration. Periodicity occurs when consistent and
regular exposure to a gas is such that clearance from the blood
is inadequate to removetheincremental gasconcentrationuntil
exposure ceases. Once the exposure resumes, incremental in-
creases in blood gas concentration resume asbefore. This pro-
cess recurs atregular intervals. Astudydemonstrating periodici-
ty is shown in Figure 4 (16).
Assuminganimal alveolarbloodconcentrations areperiodic
for the majority of the experimental exposure duration, the
NOAELIHECI forextrarespiratory effects ofgases is calculated as
in Eq. (9):
NOAEL[HECJ (mg/m3) = NOAELADJ (mg/m3) x XA/XH
(9)
where XAI/XH = the ratiooftheblood:airpartitioncoefficientof
thechemical fortheanimal species tothehumanvalue, usedonly
if XA < XH, and othervariables are as defined in Eq. (6). Ifthe
Xs are unknown or if XA > XH the default value OfXA/XH = 1
should be used.
Ifperiodicity is notachieved for90% ofthe exposureduration,
the NOAELIHECI is modified by the ratio of animal-to-human
quotients ofventilation ratedivided bybody weight as shown in
Eq. (10).
NOAELlHECI (mg/m3) = NOAELJ,JDIl (mg/m3) x (VYA/BW)A
(VH/BW)H
.00
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FIGURE 3. Plot ofNOAELHEC versus NOAELA for the rat for four possible
methods (proposed, established, similar, and optimal) of determining
NOAELHEC estimates for inhaled dichloromethane (16).
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where (VA/BW)A/(VH/BW)H = the ratio ofthe alveolar ventila-
tion rate (mL/min) divided by body weight (kg) ofthe animal
species tothe same parameters forhumans, andothervariables
are as defined in Eq. (6).
Moreuncertainty isassociated withthismethod, and amodi-
fying factor should be included. The alveolar ventilation rate
shouldbeusedtoeliminate errorassociatedwiththe areaofthe
lung that has no gas exchange with the blood.
Dose-Response Modeling
Dose-response modeling is a mathematical description re-
lating exposure to changes (e.g., toxic effects) in a biological
system. Dose-responsemodels can useallavailabledata, thereby
predicting the toxic effect over a wide range of exposures.
However, whileyieldingprecise andreproduciblepredictionsof
risk, the mathematical natureofdose-response models can lead
to overinterpretation.
Dose-response modelsshouldbeselectedbased ontheintent
oftherisk assessment. Anempirical curve-fitting model should
0.5 1.0 1.5
Time (hoursx 10-3)
2.0 2.5
FIGURE 4. Time course ofperiodicity of a 6 hr/day, 5 days/week exposure
(16).
be used if the risk at a dose within the experimental range is
desired, and amechanistic model shouldbeused topredictrisk
at a very low level below the rangeofdatapoints.
Thequality andsuitability oftoxicity data mustbe evaluated
in dose-response models. The data must be described by
mathematical constructs. Any nonlinearity in data requires at
least three data points (i.e., dose groups) to define the mathe-
matical relationship. Whenextensiveextrapolation is required,
thebiologically effectivedoseisthemostaccuratedosimetry for
predicting effects. Less desirable measures of dosimetry in
decreasing order are concentration in the affected tissue, cir-
culating blood concentration or absorbed levels, administered
dose, andenvironmental exposure. Pharmacokinetic models can
helppredicttissue levels from exposurelevels, butdata forthe
pharmacokinetic models are not usually abailable. Separate
I ~~~~Blood:Alr Pertition Coefficient a 1,000____
Fat:Blood Partition Coefficient * 100
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dose-response models mustbeevaluated foreachaffectedtissue,
andthetoxicity datashouldbesimilartotheconditions forwhich
the risk assessment isperformed, e.g., exposure route, duration,
species, agegroup, preexistinghealth, andreproductive status.
Models shouldbeselectedonthebasisofthetypeofmodel to
bedeveloped andthetypeofdataavailable. Applications ofboth
the empirical and mechanistic models are described above.
Dose-response models usequantal data regardingthepresence
or absence of an effect and the frequency of that occurrence.
These models may be threshold or nonthreshold. Threshold
models usedose aboveathreshold, andnonthresholdmodelsare
ofthe multistage, one-hit, orWeibull type. Tolerance distribu-
tion models are dose-response models that describe the prob-
ability of tolerances or thresholds in a population. The
prevalence ofeffects such as mortality are usually described in
these models.
Dose-intensity models use continuous measurements and
assumethatdeviation fromthenormal value increases with in-
creasing dose(18,19). The numerical valuederived from these
models is notan indicationofhazard. Rather, the measured ef-
fect must be compared to control populations. Theprobability
ofan effect being adverse may bederived from these models if
theprobabilitydistributionofnormal measurements isderived
first.
Dose-severity models are used when dealing with toxicity
grouped in severity categories. These models should be used
when the general severity oftoxic response is the assessment
goal. This model, liketheRfC, isdesignedtopreventadverseef-
fects regardless ofthe targetorgan. The results ofthesemodels
can be presented as probabilistic risk.
Statistical methods should be used to estimate model para-
meters, and sensitivity analyses should be conducted on all
possible parameters. Parameter values for empirical models
should be based on prior studies in similar species or with
similar chemicals. Biologically based and mechanistically bas-
ed models should use assigned parameter values from control
populations.
The quality of the dose-response model is based on its
available goodness of fit to the data and an estimate of each
parameter'svariationby amethodsuchasstandarderror. Alevel
ofstatistical significance can be applied to the model based on
its variation. If alternative assumptions are required by the
model, thentherangegeneratedbythemodel shouldbedefined.
When multiple toxic endpoints aremodeled fromanimal data,
those models applicable to the humantoxic response shouldbe
presented. Sufficient information on mechanismofaction, phar-
macokinetics, andspeciesdifferencesintolerancedistributions
should begiven inprevalencemodels torelateanimal response
rates to human response rates.
Decision Analytic Approach
Thedecisionanalyticapproach todose-responserelationships
emphasizes thecharacterizationandrepresentationofthemajor
uncertaintiesintheestimate. Probabilityisusedtoquantifythe
degree of uncertainty. These uncertainties arise because of
measurementerror, samplesize, samplingprotocol, andinsuf-
ficienthealtheffectsdata. Thejudgmentalinterpretationofprob-
ability is also known as Bayesian interpretation. The Bayesian
viewpoint isthatprobabilities represent an individual'sdegree
ofbeliefaboutagivenquantity ratherthan a measured proper-
ty ofthe world (20).
Decisionanalysispermitscharacterizationofuncertainties in
terms of probability often obtained by eliciting probabilistic
judgments from scientific experts. Such an approach has been
used forlead (5) andozone (21). Theapproach shouldbe used
when a distribution ofrisk estimates for a defined health end
point associated with given levels and conditions ofhuman ex-
posure are desired. The decision analytic approach to dose-
response assessment is more data intensive than the RfC ap-
proachandoftenrequiresanability toelicitexpertjudgmentand
thecooperationoftheseexperts. Thescientificexpertsshouldbe
recognized, competent scientists who have done research and
publishedintheareaofinterest. Theexpertsshouldrepresenta
range ofcredible scientific viewpoints.
This processbegins withdeveloping an assessmentprotocol
that guides the collection of qualitative and quantitative
judgmentsbyensuringthatquestionsarephrasedidenticallyto
allexperts, thatspecificassumptionsanddefinitionsarecommon
toallexperts, andthattheencodingprocessiscarriedoutsimilar-
ly with all participants. The appropriate health end point must
be defined for the expert participants. Exposure conditions,
populationsofinterest, andgeographical areasofinterestmust
also be defined for the experts as partoftheencoding protocol
(22).
Probabilisticdose-response relationships areobtained from
experts in an interview session. The process is referred to as
"probability encoding." Initially, the purpose ofthe session is
establishedfollowedbydefiningtheunknownquantityforwhich
judgmentwillbeelicited. Thescientificliteraturerelevanttothe
relationships and possible biases are discussed. After this
discussion, values thatbound specificprobability intervals are
determined. Experts are asked to express judgments in
probabilisticform. Theencodingprocessestablishesupperand
lowerboundsonplausibleresponserates ataspecificexposure
level, i.e, an upper response rate that would be exceeded with
probability0.01 andalowerresponseratethatwouldbeexceeded
with probability 0.99. The median response rate is also deter-
mined, whichis aresponse ratesuchthatthetrueresponse rate
isequally likely tobeaboveorbelow it. Probabilities forother
response rates are also encoded. Encoded probabilities for
several exposurelevels canbeplottedonagraph. Implications
ofthegraphofprobabilitiesarediscussedandtheexpertsallowed
to make any changes (22). These probability judgments are
checked for stability and coherence, i.e., thejudgments must
satisfy the laws ofprobability such asadditivity.
Whenanadequatedatabaseisavailable, aprobabilisticdose-
responserelationshipandanestimateofuncertaintycanbeob-
tained. However, sincetheassessmentmustbe forhumans and
thepopulationfromwhichthedatawasdrawnislikelytobefrom
animals, extrapolationisrequired. Probabilisticdose-response
relationshipscanbepresentedascurvesonagraphofdoseorex-
posure versus response rate. The curves can consistofthe0.5,
0.05, and 0.95 fractile distributions. The0.05 and0.95 fractile
distributions bound the 90% credible interval, i.e., 0.9 prob-
ability that the "true" dose-response relationship lies in the
designatedrange. Eachexpert's90% credibleintervalcanthen
becomparedtoassessatotal rangeforthe0.9probabilityofthe
"true" doseresponse curve.
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Structure-Activity Relationships
Structure-activity relationships may be used in the hazard
identification step when very little orno testdata areavailable.
The approach contains four elements: a) evaluating pertinent
data on the chemical under study; b) evaluating data on an
analogous chemical; c) using mathematical expressions for
biological activity; andd)interpretatingandintegratingavailable
information.
Thechemical understudy oritspotential metabolite mustbe
evaluated andinterpreted. Thisevaluation mustincludephysical
andchemicalparametersthataffectthetoxicityofthechemical.
Analogouschemicals mustalsobeevaluated. Two factorsare
used to define chemicals as analogous: structural, functional,
andmechanistic similaritiesthatcontrolthebiologicalreactivity
ofthechemicals andavailability ofpertinent toxicologic infor-
mation on the analogues. An effort should be made to select
analogueswithsimilarstructuralandsubstructuralcomponents
that also have similar biological activity. Potential metabolic
pathways should be considered to identify key potential
metabolites. Oncealistofchemicalshavingsimilarstructureor
similarmetabolitesareidentified, thesechemicalsaresearched
on an available toxicity database to identify relevant toxicity
literature necessary in completing thehazard identification.
Quantitative structure-activity relationships that are mathe-
matical expressions ofbiological activity are used to estimate
physical andchemical properties, e.g., watersolubility, partition
coefficient, vapor pressure. The water solubility is akey com-
ponent when considering the dermal, pulmonary, or
gastrointestinal absorptionofachemical. Thus, thephysicaland
chemical properties ofan analogue in addition to its structural
properties may be important in selecting the most similar
analogue.
Finally, theavailable information mustbeinterpretedby scien-
tificassessors. Theinformationdevelopedinthepreceding steps
onanalogous substances and metabolites will likely be limited
insome respectsandthereforerequirejudgmentand integration.
Thedataonanaloguesshouldbeevaluatedbasedonthesimilari-
ty to the chemical under study, and metabolites should be
evaluated based on their formation and toxicological sig-
nificance. Parameters to be evaluated are dermal, pulmonary,
andgastrointestinal absorption; distribution andexcretion; and
possible mechanisms oftoxicity andtheability ofthechemical
anditsanaloguestooperateby suchmechanisms. Thegreaterthe
similaritybetweenthechemical inquestionanditsanalogues, the
more reliable the hazard identification.
Summary
Risk assessments from exposure to indoor airpollutants re-
quire exposure assessments and dose-response assessments.
Dose-response assessmentmethodologies havebeendiscussed
here. Thesemethodsincludetheinhalation referenceconcentra-
tion, structure-activity relationships, dose-response models,
andthedecisionanalyticapproach. TheRfCisanestimate(with
uncertainty spanningperhapsanorderofmagnitude)ofadaily
exposure to the human population (including sensitive
subgroups) that is likely to be without an appreciable risk of
deleterious effects during a lifetime. The current RfC method
provides guidelines for making the necessary dosimetric ad-
justments forgases andaerosols. Humanequivalentconcentra-
tionsforno-observed-adverse-effect levels inanimalsaredeter-
mined by using mathematical relationships that adjust for
regional deposition, solubility, ventilation rate, and blood:air
partition coefficients. Physiologically based pharmacokinetic
models can also be used in some cases to predict the human
equivalent concentration more accurately. Dose-response
modeling, although very data intensive, describes the dose-
response relationship over the entire range ofdata and can be
modified to address different assessment goals. The decision
analytic approach todose-response assessment can be used to
obtain a distribution ofrisk estimates for a defined health end
pointbyusingexpertjudgmentregardingthedose-responserela-
tionship. Structure-activity relationships maybeusedforhazard
identification when few or no test data exist, and chemical
analogues can be identified which have similar structural,
metabolic, and toxic effects as thechemical ofconcern.
The RfC methodology exists as an interim methodology.
Futurescientificadvancements areexpectedtofurtherrefinethe
approach. Quantitation andreductionofuncertaintyarethesub-
jectofcurrent researchdesigned toimprovethisdose-response
methodology. In addition to the analysis ofuncertainty for the
RfC methodology, physiologically based pharmacokinetic
models are being actively pursued for many chemicals. These
models will reducetheuncertaintyofextrapolationfromanimals
tohumans. Research intoroute-to-routeextrapolation will fur-
ther expand the scope of the RfC procedure. Research into
biologically baseddose-response models andmixtures areother
areasthatwill reduceuncertainty indose-responsemodelsand,
therefore, in indoor air riskassessments in the future.
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